Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
7. lappuse
... Subpart A [ Reserved ] Subpart B - Combination Drugs 300.50 Fixed - combination prescription drugs for humans . Subpart C - Substances Generally Prohibited From Drugs 300.100 Chlorofluorocarbon propellants . AUTHORITY : 21 U.S.C. 331 ...
... Subpart A [ Reserved ] Subpart B - Combination Drugs 300.50 Fixed - combination prescription drugs for humans . Subpart C - Substances Generally Prohibited From Drugs 300.100 Chlorofluorocarbon propellants . AUTHORITY : 21 U.S.C. 331 ...
8. lappuse
... Subpart D - Records and Reports 310.303 Continuation of long - term studies , records , and reports on certain drugs for which new drug applications have been approved . 310.305 Records and reports concerning ad- verse drug experiences ...
... Subpart D - Records and Reports 310.303 Continuation of long - term studies , records , and reports on certain drugs for which new drug applications have been approved . 310.305 Records and reports concerning ad- verse drug experiences ...
24. lappuse
... Subpart E - Requirements for Specific New Drugs or Devices §310.500 Digoxin products for oral use ; conditions for marketing . ( a ) Studies have shown evidence of clinically significant differences in bio- availability in different ...
... Subpart E - Requirements for Specific New Drugs or Devices §310.500 Digoxin products for oral use ; conditions for marketing . ( a ) Studies have shown evidence of clinically significant differences in bio- availability in different ...
61. lappuse
... subpart E , ef- fective Apr. 20 , 1998 . PART 312 - INVESTIGATIONAL NEW DRUG APPLICATION Sec . Subpart A - General Provisions 312.1 Scope . 312.2 Applicability . 312.3 Definitions and interpretations . 312.6 Labeling of an ...
... subpart E , ef- fective Apr. 20 , 1998 . PART 312 - INVESTIGATIONAL NEW DRUG APPLICATION Sec . Subpart A - General Provisions 312.1 Scope . 312.2 Applicability . 312.3 Definitions and interpretations . 312.6 Labeling of an ...
62. lappuse
... Subpart G - Drugs for Investigational Use in Laboratory Research Animals or in Vitro Tests 312.160 Drugs for investigational use in lab- oratory research animals or in vitro tests . AUTHORITY : 21 U.S.C. 321 , 331 , 351 , 352 , 353 ...
... Subpart G - Drugs for Investigational Use in Laboratory Research Animals or in Vitro Tests 312.160 Drugs for investigational use in lab- oratory research animals or in vitro tests . AUTHORITY : 21 U.S.C. 321 , 331 , 351 , 352 , 353 ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning